Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barzolvolimab in Chronic Inducible Urticaria
NCT05405660Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of barzolvolimab in chronic inducible urticaria (CIndU), sponsored by Celldex Therapeutics. Started Jun 2022; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT05405660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405660.